

Article

# Long-term antibody response against SARS-CoV-2 in Health Care Workers: Effectiveness of homologous and heterologous regimens and their relation to systemic vaccine-associated symptoms

Helene Kierkegaard <sup>1,2,\*</sup> , Birgit Thorup Røge <sup>2</sup>, Amanda Nissen <sup>1</sup> and Jonna Skov Madsen <sup>1,3</sup>

<sup>1</sup> Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, 6000 Kolding, Denmark;

<sup>2</sup> Department of Internal Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, 6000 Kolding, Denmark.

<sup>3</sup> Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, 5230 Odense, Denmark

\* Correspondence: Helene Kierkegaard: heki@dadlnet.dk

**Abstract:** This prospective study provides data on long-term humoral immunogenicity of a heterologous off-label vaccine regimen combining the adenoviral vectored ChAdOx1 nCoV-19 from Astra-Zeneca (ChAd) with the mRNA-1273 vaccine from Moderna (m1273) in comparison to two different homologous mRNA vaccine schedules. Of the 316 COVID-19 naïve adult health care workers (HCW) included to complete a survey on vaccine-associated symptoms (VAS), 197 had received the homologous BNT162b2 mRNA vaccine from Pfizer/BioNTech (BNT/BNT), 76 the homologous m1273/m1273, and 43 the heterologous ChAd/m1273 vaccine regimen. Concentration of antibodies against SARS-CoV-2 spike protein in plasma 5-7 months after the second vaccine dose was higher in the m1273/m1273 and ChAd/m1273 than the BNT/BNT vaccine group. The frequency of systemic VAS after first vaccine dose was 86% after ChAd compared to 35% and 39% after BNT and m1273, respectively ( $p < 0.0001$ ), and after second vaccine dose highest (89%) in the m1273/m1273 group ( $p < 0.001$ ). Individuals with systemic VAS achieved higher levels of antibodies irrespective of vaccine regimen. In conclusion, VAS serve as a strong predictor of long-term humoral immune response, and the heterologous ChAd/m1273 vaccine regimen provides an at least equal long-term humoral immune response compared with the standard vaccine regimens used in Denmark.

**Keywords:** COVID-19 vaccines; vaccine effectiveness; BNT162b2 vaccine; mRNA-1273 vaccine; ChAdOx1 vaccine; 19 Elecsys Anti-SARS-CoV-2 S assay; reactogenicity; vaccine-associated symptoms

## 1. Introduction

Vaccination against SARS-CoV-2 plays a major role in controlling the SARS-CoV-2 pandemic. Front-line health care workers (HCW) were prioritized to be among the first to receive the primary vaccines in Denmark, in addition to those at high risk of severe disease and death due to COVID-19. At the turn of the year 2020, the BNT162b2 mRNA vaccine from Pfizer/BioNTech (BNT) was put into use, followed by the introduction of the mRNA-1273 vaccine from Moderna (m1273) 14 January 2021. The viral vector ChAdOx1 vaccine from AstraZeneca (ChAd) was then introduced 25 days later on 9 February and used until 11 March 2021, at which time this vaccine was excluded from the Danish vaccination program due to rising concerns of Vaccine-Induced Immune Thrombosis and Thrombocytopenia (VITT)[1]. Thus, no one received a second dose of the ChAd vaccine at our hospital. According to recommendations from the Danish Health Authority in April 2021, individuals who had received a single ChAd vaccine dose were to be offered a second vaccine dose with one of the two used mRNA vaccines. For this purpose, our hospital used the m1273 vaccine, leaving a proportion of HCWs to receive the heterologous vaccine schedule ChAd/m1273.

Concerns were soon raised about waning vaccine immunity and the safety of heterologous schedules. A large Danish population-based study found a reduced risk of SARS-CoV-2 infection in individuals who had received the heterologous ChAd/m1273 vaccine schedule compared to unvaccinated individuals, which provided evidence for its clinical effectiveness[2]. However, the study also stated the need for a longer follow-up time as well as longitudinal data on the duration of vaccine-induced antibody levels obtained by this heterologous and other vaccine regimens[2]. A randomized study investigating the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines found that the SARS-CoV-2 anti-spike IgG concentrations measured 28 days after the second dose were higher than what was obtained with the homologous ChAd/ChAd schedule. The heterologous ChAd/BNT showed a lower SARS-CoV-2 anti-spike IgG concentration compared to the homologous BNT/BNT regimen[3], whereas Schmidt et al. found that the same antibody level was obtained when comparing the BNT/BNT and the ChAd/BNT schedules[4].

A recent comprehensive review provides data on vaccine effectiveness for five homogeneous and four heterologous COVID-19 vaccine regimens and offers solid evidence for the clinical effectiveness of the homologous vaccine regimens, especially the mRNA vaccines[5]. However, data on most of the heterologous regimens are sparse, and the review does not include information on the ChAd/m1273 regimen used at our hospital[5]. This calls for more data on the safety and effectiveness of these heterologous vaccine regimens, also given the fact they have been applied by several countries in response to changing recommendations and vaccine shortages. In addition to the call for further studies on other, new or updated vaccine regimens, there is also a need to evaluate waning immunity in different vaccine regimens and to determine which factors might predict vaccine effectiveness. Consequently, a number of studies have proposed and addressed an association between vaccine-associated symptoms and vaccine effectiveness. Here, adverse reactions after the homologous mRNA vaccines BNT/BNT and m1273/m1273 were associated with higher antibody levels in some [6–9] but not all studies[10]. No such association was found for the homologous ChAd/ChAd vaccine in a prospective observational study[11].


The primary aim of this prospective study was to determine and compare antibody levels obtained by three different vaccine regimens used in HCWs in a Danish medical center; the two homologous mRNA vaccines BNT/BNT or m1273/m1273 and the heterologous ChAd/m1273 vaccine regimen. The secondary aim was to investigate the association between systemic vaccine-associated symptoms and long-term antibody response.

## 2. Materials and Methods

### 2.1. Study population and design

In this prospective study, we recruited HCWs employed at Lillebaelt Hospital, University Hospital of Southern Denmark to participate in a survey on vaccine-associated symptoms (VAS) via the hospital's internal website. Online recruitment was initiated on 25 February 2021. In addition, we consecutively invited the first 115 volunteers with no history of PCR-verified COVID-19 to participate in an antibody sub-study to determine long-term antibody response.

The heterologous ChAd/m1273 vaccine regimen was introduced in April 2021 for those HCWs who had received their first vaccine dose with the ChAd vaccine. Thus, in May 2021 there was an additional call to recruit individuals from this heterologous vaccine group. Finally, as the homologous BNT/BNT was by far the most prominent vaccine regimen used, a last call was announced in September 2021 to recruit more individuals in the heterologous ChAd/m1273 and the homologous m1273/m1273 vaccine regimen groups. The last blood sample was collected on 2 December 2021. The study outline and flow are presented in Figure 1.



**Figure 1.** Outline of the study flow illustrating the timeline for recruiting participants according to vaccine regimens. Green: BNT/BNT, blue: m1273/m1273, and purple: ChAd/m1273 vaccine regimen. Early and late measurement refers to antibody level on average one and six months after completion of a vaccine regimen with a second vaccine dose, respectively.

Participants completed a structured questionnaire on systemic and local VAS, vaccine regimen, and known preexisting co-morbidities in addition to information on any positive PCR-test for SARS-CoV-2, both before and after the first vaccine dose and during the entire follow-up period until the late antibody measurements. Systemic VAS were defined as chills, fever, fatigue, muscle pain, headache, or nausea. The full-length questionnaire is provided in supplementary Table S1.

Blood samples for early and late antibody response were drawn 1 and 6 (+/-) months after the second vaccine dose, centrifuged at 2000 g for 10 min and plasma transferred to cryotubes and stored at -80C until analysis.

## 2.2. SARS-CoV-2 Antibody Measurement

Quantitative measurement of antibodies against SARS-CoV-2 spike (S) protein in all plasma samples were analyzed blinded to clinical data using Elecsys® Anti-SARS-CoV-2 S immunoassay on the Cobas e 801 platform (Roche Diagnostics GmbH, Germany). The immunoassay uses a recombinant protein representing the receptor-binding domain (RBD) of the S antigen. According to the manufacturer, the unit U/mL for the Elecsys Anti-SARS-

CoV-2 S assay is equivalent to the Binding Antibody Unit (BAU/mL) for the First WHO International Standard for anti-SARS-CoV-2 immunoglobulin. The measuring range for the assay is 0.4 U/mL to 2500 U/mL, and values above 0.8 U/mL are interpreted as positive. All analyses were carried out at the Department of Biochemistry and Immunology, Lillebaelt Hospital, which is accredited by Danish Accreditation Fund (DANAK) according to the ISO 15189:2012 standard that specifies requirements for quality and competence in medical laboratories.

### 2.3. Statistical analysis

Values are reported as medians with ranges or interquartile ranges (IQR) and n (%). Differences between groups were tested with the Kruskal-Wallis non-parametric test or the Chi-Square test. The odds ratio was adjusted for age by logistic regression, and the presence of systemic VAS was correlated with the level of antibodies at the late measurement 6 months after completion of the vaccine regimen with a second vaccine dose. The graphical presentations and data analysis were performed using SAS® Enterprise Guide, Version 7.15, SAS Institute Inc. Cary, NC, USA and R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. A *p* value < 0.05 was considered statistically significant.

## 3. Results

### 3.1. Study participants and vaccine regimens

The online questionnaire was answered by 337 HCWs, of which 209 received the BNT/BNT, 82 the m1273/m1273, and 46 the ChAd/m1273 vaccine regimen. Of these, 12 individuals in the BNT/BNT, 6 in the m1273/m1273, and 3 the ChAd/m1273 group reported PCR-confirmed SARS-CoV-2 infection prior to the first vaccine dose. No one reported PCR-confirmed SARS-CoV-2 infection between the first and second vaccine doses, leaving 197, 76, and 43 for the data analyses of VAS, respectively.

The timespan between the first and second vaccine doses for the homologous vaccine regimens followed the manufacturers' recommendations. No such recommendation exists for the heterologous vaccine regimen, which was awaited government approval to be introduced. Thus timespan between the first and second vaccine doses was longer in the heterologous ChAd/m1273 vaccine group than in the two homologous vaccine groups. The median timespan between the first and second vaccine doses is 85 days (range, 40–85) days in the ChAd/m1273 vaccine group, compared with 28 (20–60) and 36 (29–43) days in the BNT/BNT and m1273/ m1273 vaccine group, respectively. Therefore, individuals in the heterologous ChAd/m1273 vaccine group completed the vaccine program later, and the average time between early and late antibody measurements was shorter than it was for individuals receiving one of the two homologous vaccine regimens. The diagram for the study flow is presented in Figure 1, and Table 1 provides the characteristics of study population according to vaccine regimen together with vaccine-associated symptoms.

**Table 1.** Characteristics of the cohorts according to vaccine regimen.

	BNT/BNT	m1273/m1273	ChAd/m1273	p-value <sup>1</sup>
Answers on questionnaire, n	209	82	46	
PCR-confirmed SARS-CoV-2 infection prior to first vaccine dose, n (%) (PP)	12 (6%)	6 (7%)	3 (7%)	0.88
PCR-confirmed SARS-CoV-2 during follow up, n	1	6	0	
<b>Study cohort excluding individuals with PCR-confirmed SARS-CoV-2 infection prior to first vaccine dose</b>				
<b>Demographics</b>				
HWCs (N)	197	76	43	
Sex: female (%)	185 (94%)	70 (92%)	39 (90%)	0.70
Age: median (range), years	48 (19-67)	50 (21-67)	45 (24-64)	0.56*
Preexisting co-morbidity	48 (24%)	23 (30%)	9 (21%)	0.47
<b>Vaccine-associated symptoms</b>				
<i>Systemic symptoms</i>				
After the first dose	69 (35%)	30 (39%)	37 (86%)	<0.0001
After the second dose	127 (64%)	68 (89%)	33 (77%)	<0.001
After any dose	140 (71%)	69 (91%)	42 (98%)	<0.0000001
<i>Local symptoms</i>				
After the first dose	162 (82%)	71 (93%)	36 (84%)	0.06
After the second dose	137 (70%)	71 (93%)	33 (80%)	<0.001
After any dose	174(88%)	75(99%)	38(93%)	0.02
Any VAS after any dose	191 (97%)	76 (100%)	43 (100%)	0.16

<sup>1</sup> All p-values are calculated with Chi-Square test, except for the number marked with\* where the non-parametric Kruskal-Wallis test is used. VAS: Vaccine-associated symptoms. HWCs health care workers.


### 3.2. Vaccine-associated symptoms

The frequency of reported systemic symptoms after the first vaccine dose was 86% in individuals receiving the ChAd vaccine compared to 35% and 39% in those receiving the BNT and m1273 vaccine, respectively ( $p < 0.0001$ ). However, the frequency of systemic VAS after the second vaccine dose was highest in those receiving the m1273/m1273 vaccine regimen compared to those receiving either the BNT/BNT or the ChAd/m1273 vaccine regimen, overall  $p$ -value  $< 0.001$ . HCWs with systemic VAS after any dose were younger than HCWs without systemic VAS (Kruskal-Wallis non-parametric test  $p = 0.011$ .) Median age for each group are listed in Figure 4. Preexisting co-morbidity showed no association with systemic VAS (Chi-Square test  $p = 0.58$ , data not shown).

### 3.3. Early and late antibody level according to vaccine regimen

After we excluded individuals who reported having a positive PCR test for SARS-CoV-2 prior to the first vaccine dose, blood samples for antibody measurement was available from a total of 172 individuals (160 females) within the age range of 24–67 years. Data on early antibody levels measured median 31 (IQR 12) days after the second vaccine dose was available from 126 individuals, whereas data on late antibody levels measured median 218 (IQR 21) days after the second vaccine dose was available from 142 individuals, and combined early and late antibody level from 96 individuals. Early and late antibody levels according to vaccine regimen are presented in Figure 2.

Figure 2.




	BNT/BNT		m1273/m1273		ChAd/m1273	
Measurement	Early	Late	Early	Late	Early	Late
<b>N</b> ( <i>N</i> -paired)	76 (62)	62 (62)	31(24)	46 (24)	19 (10)	34 (10)
<b>Days after 2nd dose</b> median ( <i>IQR</i> )	38 (12)	228 (19)	28 (2)	218 (9)	19 (11)	164 (29)
<b>Antibodies, U/mL</b> median ( <i>IQR</i> )	2409 (1314)	583 (511)	> 2500 (0)	1125 (1158)	>2500 (0)	1310 (1364)
<b>Antibodies, U/mL</b> median ( <i>IQR</i> )	49 (22)	50 (22)	50 (13)	51 (12)	54 (21)	45 (22)

**Figure 2.** Concentration of antibodies against SARS-CoV-2 spike (S) protein in plasma at late and early measurements according to vaccine regimen. Results are presented as box plots, where the ends of the boxes define the 25th and 75th percentiles and with a line at the median. Individual values for each vaccine group appear as green circles (BNT/BNT), blue squares (m1273/m1273) and purple diamonds (ChAd/m1273). Individuals with paired measurements (both early and late antibody measurements in the same person) are marked with a line combining the two measurements. N is the number of individuals in each vaccine group and N-paired is the number of individuals with paired measurements. The red circle indicates one participant with a PCR-confirmed infection with SARS-CoV-2 between early and late test. Interquartile range (IQR) indicate the difference between 75th and 25th percentile.

The early level of antibody obtained was higher in individuals receiving the homologous m1273/m1273 or the heterologous ChAd/m1273 vaccine regimen than in those who

received the BNT/BNT vaccine regimen. Thus, at the early measurement all individuals except one in both the m1273/m1273 and the ChAd/m1273 vaccine group obtained levels of antibodies above 2500 U/mL, which is the upper measuring range for the assay. In the BNT/BNT vaccine group the median (IQR) antibody concentration was 2409 (1314) U/mL. Kruskal Wallis non-parametric test of the difference between the three groups was highly significant, with an overall p-value  $< 0.0001$ , BNT/BNT vs m1273/m1273,  $p < 0.0001$ , BNT/BNT vs ChAd/m1273,  $p = 0.0004$ . This difference in antibody level between the m1273/m1273 or ChAd/m1273 groups and the BNT/BNT vaccine group remained at the late measurement 5–7 months after completion of the vaccine regimen with the second dose. No significant difference in antibody levels between the m1273/m1273 and the ChAd/m1273 vaccine group could be demonstrated at either early or late measurements.




**Figure 3.** Concentration of antibodies against SARS-CoV-2 spike (S) protein in plasma after completion of the vaccine regimen with the second dose of vaccine. Green circle: BNT/BNT. Blue square: m1273/m1273. Purple diamond: ChAd/m1273. Paired measurements are marked with lines. The individual marked with red had a PCR-confirmed infection with SARS-CoV-2 between the early and late antibody measurement

Regardless of the vaccine regimen received, the 96 paired dataset demonstrated lower antibody level at late compared to early measurements in all groups ( $p < 0.001$ ). No difference in the waning of antibodies could be demonstrated between groups ( $p = 0.44$ , data not shown). Figure 3 outlines the dynamic of antibody level over time after completion of the vaccine regimen. One participant in the BNT/BNT vaccine group who had a PCR-confirmed break-through infection 5 months after the second dose of BNT vaccine achieved an antibody concentration above the upper measuring limit at the late measurement. In addition, in the m1273/m1273 vaccine group, one participant with known medical treated autoimmune disease did not achieve a measurable humoral immune response. This is illustrated Figure 2 and Figure 3.

### 3.4. Vaccine-associated symptoms predict late antibody level

Figure 4 illustrates that individuals with systemic VAS after any dose achieved a higher level of antibodies compared to those with only local or no VAS ( $p < 0.0001$ ). The likelihood of having an antibody level above 700 U/mL measured at long-term follow up was associated with systemic VAS, odds ratio (OR) 5.42, (95% CI 2.15–13.67,  $p = 0.0002$ ) and remained significant after adjusting for age. Thus, the age adjusted OR was 5.15 (95% CI 2.00–13.25,  $p = 0.0008$ ).

Figure 4.



	BNT/BNT			m1273/m1273		ChAd/m1273	
Vaccine-associated symptoms	None	Local	Systemic	Local	Systemic	Local	Systemic
N	2	17	43	5	41	2	32
Days after 2nd dose median (IQR)	230 (3)	223 (23)	228 (23)	217 (1)	218 (9)	143 (11)	165 (29)
Antibodies, U/mL median (IQR)	112 (57)	395 (331)	729 (503)	1090 (1222)	1150 (1008)	1415 (590)	1450 (1415)
Antibodies, U/mL median (IQR)	55 (8)	56 (15)	49 (21)	55 (3)	50 (12)	58 (5)	45 (23))

**Figure 4.** Concentration of antibodies against SARS-CoV-2 spike (S) protein in plasma 5 to 7 months after completion of vaccine regimen with the second dose of vaccine according to vaccine regimen and vaccine associated symptoms (VAS). Results are presented as both individual values, as box plots, where the ends of the boxes define the 25th and 75th percentiles, and with a line at the median. None refers to no VAS; Local refers to local VAS, and Systemic to systemic VAS. Interquartile range (IQR) indicate the difference between 75th and 25th percentile.

#### 4. Discussion

In the current longitudinal study, we compare the long-term humoral response to three different vaccines against SARS-CoV-2 used in a cohort of SARS-CoV-2 naïve Danish HCWs. We provide evidence that both the effectiveness and durability of the humoral immune responses induced by the heterologous off-label ChAd/m1273 vaccine regimen is at least equivalent to the homologous standard vaccine regimens with either BNT/BNT or m1273/m1273 used in Denmark. In addition, the antibody level 5 to 7 months after the second vaccine dose is higher in individuals with systemic VAS than in individuals with no or only local reactions/symptoms after vaccination. VAS as a predictor for

vaccine effectiveness adds to the findings of other studies[6–9] and serves as reassuring knowledge when caring for patients experiencing VAS. A recent comprehensive review on vaccine effectiveness provides solid evidence for the clinical effectiveness of the homologous vaccine regimens, particularly the mRNA vaccines[5]. However, data for most of the heterologous regimens included in this paper was limited, and no data were provided on the heterologous ChAd/m1273 vaccine regimen[5]. This calls for additional data on the clinical effectiveness and safety of heterologous vaccine regimens, especially since several countries have applied heterologous vaccine regimens in response to changing recommendations and vaccine shortages. There is also a need for longitudinal data on the duration of vaccine-induced antibody levels to provide information on both the level and duration of protecting antibodies obtained by different vaccine schedules.

In our study, the early and late measurement of antibodies against SARS-CoV-2 spike (S) protein in plasma took place 1 and 5–7 months after the second vaccine dose completing the primary vaccine regimen. We found the early antibody concentration to be significantly higher in individuals receiving the homologous m1273/m1273 or the heterologous ChAd/m1273 vaccine regimen than in those receiving the BNT/BNT vaccine. In comparison, a randomized study investigating the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines found that the obtained antibody concentrations of both heterologous schedules measured 28 days after the second dose were higher than with the homologous ChAd/ChAd schedule. However, they found that antibody concentration was lower in the heterologous ChAd/BNT than in the homologous BNT/BNT regimen[3], which contradicts what we found in our heterologous ChAd/m1273 vaccine regimen compared with the homologous BNT/BNT regimen. A study by Schmidt et al. found similar antibody levels 2 weeks after the second vaccine dose when comparing homologous mRNA vaccine regimens (BNT162b2 or mRNA-1273) and heterologous ChAd/mRNA vaccine schedules. This study however, does not distinguish between the two mRNA vaccines (BNT162b2 or mRNA-1273) in the data analysis[4].

The long-term humoral response in our study was assessed by concentration of antibodies against SARS-CoV-2 spike (S) protein 5–7 months after the completion of the vaccine regimen with the second vaccine dose. At this long-term follow up, we found that the antibody concentration in individuals receiving the homologous m1273/m1273 or the heterologous ChAd/m1273 vaccine regimen was higher than that of those receiving the homologous vaccine regimens with BNT/BNT. Furthermore, by mutual comparison the concentration of antibodies were higher in individuals receiving the heterologous ChAd/m1273 compared with the homologous m1273/m1273 vaccine regimen. This, however, we attribute to be a consequence of the waning of antibodies over time, where, in individuals receiving the heterologous ChAd/BNT vaccine regimen the antibody level was measured median 164 days after the second vaccine dose compared with 218 and 228 days in those receiving the homologous m1273/m1273 or BNT/BNT vaccine regimen, respectively. Therefore, we do not consider our results allow concluding a superiority in long-term humoral immune response for the heterologous ChAd/m1273 vaccine regimen. However, it provides an at least equal long-term humoral immune response compared with the two homologous standard vaccination regimens, BNT/BNT and m1273/m1273, used in Denmark.

A recent study from Greece provide data on a homologous ChAd/ChAd vaccine regimen, and compare the long-term antibody response of this regimen with the homologous BNT/BNT vaccine regimen, and found the BNT/BNT vaccine to be superior with higher levels of antibodies at both 3 and 6 months post vaccination[12]. Similarly, a short-term study comparing these two vaccine regimens (BNT/BNT and ChAd/ChAd) found higher antibody concentrations 2 weeks after the second vaccine dose in the BNT/BNT compared to the ChAd/ChAd vaccine group[13]. Thus, in these two studies the homologous BNT/BNT vaccine regimen obtained a higher long-term antibody level than the homologous ChAd/ChAd vaccine regimen [12,13], whereas in our study the ChAd vaccine when part of the heterologous ChAd/m1273 vaccine regimen performed better than the

homologous BNT/BNT vaccine regimen. Other recent studies also suggest that the heterologous vaccine regimens have the advantage of achieving a protective level of antibodies. Thus, a study with 84 days of follow-up shows superior antibody immunity induced by the heterologous ChAd1/m1273 than the homologous ChAd/ChAd vaccine regimen[14]. In addition, a study that measured both level of antibodies and memory B cell responses on the day of vaccine regimen completion with the second vaccine dose and again after 7 to 9 days found that individuals who received the heterologous ChAdOx1/m1273 vaccine obtained a higher level of antibodies than those who received the homologous ChAd/ChAd vaccine regimen[15]. Several heterologous vaccine regimens are being applied in multiple countries in response to changing recommendations and vaccine shortages. This highlights the need for data on the effectiveness and safety of these regimens. In addition, there is a need for further studies to evaluate waning immunity in other, new or updated vaccine regimens and to determine the factors that might predict this.

## 5. Conclusions

Vaccine-associated symptoms are a strong predictor of vaccine effectiveness, based on long-term humoral response. The heterologous ChAd/m1273 vaccine regimen provides an at least equal long-term humoral immune response compared with the two homologous standard vaccine regimens, BNT/BNT or m1273/m1273, used in Denmark. Future studies are needed to provide data on effectiveness and safety of each vaccine regimen. Still especially data on the heterologous vaccine regimens are sparse; through multiple countries use these regimens in response to changing recommendations and vaccine shortages. Further, there is a need to investigate who will need and when a booster vaccine dose is necessary.

**Author Contributions:** Conceptualization, H.K. and B.T.R.; validation, A.L.; formal analysis, H.K.; investigation, H.K. and A.L.; resources, J.S.M.; data curation, H.K.; writing—original draft preparation, H.K. and B.T.R.; writing—review and editing, J.S.M, H.K., B.T.R. and A.L.; visualization, H.K.; supervision, J.S.M. and B.T.R.; project administration, H.K.; All authors have read and agreed to the published version of the manuscript

**Funding:** This research received no external funding

**Institutional Review Board Statement:** The study was approved by Region of Southern Denmark (Journal approval no.: 21/478) and performed according to the Danish data protection laws and the Danish health legislation § 42 in accordance with the Helsinki Declaration.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Not applicable

**Acknowledgments:** The authors are grateful to biomedical laboratory scientists at Lillebaelt Hospital for blood sampling and analysis, in particular Birgitte Knudsen and Mette Kondadi. We thank the HCWs for participating in our study.

**Conflicts of Interest:** The authors declare no conflict of interest

## Abbreviations

The following abbreviations are used in this manuscript:

VAS	Vaccine-associated symptoms
BNT	BNT162b2 mRNA vaccine from Pfizer/BioNTech
ChAd	ChAdOx1 nCoV-19 from AstraZeneca
m1273	mRNA-1273 vaccine from Moderna
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
HCW	health care workers
VITT	Vaccine-Induced Immune Thrombosis and Thrombocytopenia
COVID-19	Coronavirus disease 2019

## References

1. Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *Bmj* **2021**, 373:n1114.
2. Gram MA, Nielsen J, Schelde AB, Nielsen KF, Moustsen-Helms IR, Sørensen AKB, et al. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study. *PLoS Med.* **2021**, *18*, e1003874.
3. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet* **2021**, *398*, 856-69.
4. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. *Nat Med.* **2021**, *27*, 1530-5.
5. Hatcher SM, Endres-Dighe SM, Angulo FJ, Srivastava A, Nguyen JL, Khan F, et al. COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1 January-30 June 2021). *Vaccines (Basel)* **2022**, *10*
6. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. *Diagnostics (Basel)* **2020**, *10*
7. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, et al. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. *Diagnostics (Basel)* **2021**, *11*
8. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Declined antibody responses to COVID-19 mRNA vaccine within first three months. *medRxiv.* **2021**, 2021.04.19.21255714.
9. Yamamoto S, Fukunaga A, Tanaka A, Takeuchi JS, Inoue Y, Kimura M, et al. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. *Vaccine* **2022**, *40*, 1924-7.
10. Coggins SA, Laing ED, Olsen CH, Goguet E, Moser M, Jackson-Thompson BM, et al. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. *Open Forum Infect Dis.* **2022**, 9:ofab575
11. Lee SW, Moon JY, Lee SK, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. *Front Immunol.* **2021**, *12*, 779212.
12. Terpos E, Karalis V, Ntanasis-Stathopoulos I, Evangelakou Z, Gavriatopoulou M, Manola MS, et al. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. *Biomedicines.* **2022**, *10*
13. Kim JY, Lim SY, Park S, Kwon JS, Bae S, Park JY, et al. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. *J Infect Dis.* **2022**, *225*, 777-84.
14. Sheng WH, Chang SY, Lin PH, Hsieh MJ, Chang HH, Cheng CY, et al. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination. *J Formos Med Assoc.* **2022**, *121*, 766-77.
15. Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.. *Science* **2022**, *375*, 1041-7.